ReviewFrontiers in bioengineering and biotechnology2025
A call for congressional action: revisiting the U.S. coordinated framework for the regulation of biotechnology.
Review in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Synthetic biology and genome engineering in support of human, agricultural, and environmental security.Frontiers in bioengineering and biotechnology · 2026Article
- A standard-curve-free ΔΔCt method for rapid GMO compliance screening relative to labeling thresholds.Frontiers in plant science · 2026Article
- Engaging U.S. experts in environmental oversight of GE crops as it relates to novel biotechnologies.Frontiers in bioengineering and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the 1986 release of the Coordinated Framework for the Regulation of Biotechnology almost 40 years ago, there have been two whole of government updates that made only minor changes, while new regulations and guidance from individual agencies have made more substantial alterations. Despite scientific advances and the emergence of products that fall outside the purview of legacy statutes, repeated calls for substantive changes have gone largely unanswered. We expand upon the NSCEB's most important recommendations for improvements to the Coordinated Framework. We recommend that Congress create an NBCO and direct it to create a centralized application submission portal; conduct horizon scanning for future products of biotechnology; streamline regulations for familiar products and exempt low-risk products; and improve organizational structure, staff training, and interagency exchange.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.